Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Smith VK, Mansfield CA, Klaiber HA. Terrorist threats, information disclosures, and consumer sovereignty. Information economics and policy. 2013 Dec;25(4):225-34.